| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Péter Gaszne. [About the curability of schizophrenia]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. vol 7. issue 1. 2005-11-01. PMID:16167467. |
the curability of schizophrenia is not clear, but in this case report we describe a paranoid schizophrenic patient who has remained symptom-free during three decades of treatment with clozapine. |
2005-11-01 |
2023-08-12 |
Not clear |
| Amani Eltayb, Marie-Louise G Wadenberg, Torgny H Svensso. Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. Biological psychiatry. vol 58. issue 4. 2005-10-27. PMID:16102547. |
clozapine shows superior efficacy in schizophrenia and enhances prefrontal dopamine (da) output like other atypical, but not typical, antipsychotic drugs (apds). |
2005-10-27 |
2023-08-12 |
Not clear |
| Joseph M Pierr. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management. Drug safety. vol 28. issue 3. 2005-10-26. PMID:15733025. |
the treatment of schizophrenia changed drastically with the discovery of antipsychotic medications in the 1950s, the release of clozapine in the us in 1989 and the subsequent development of the atypical or novel antipsychotics. |
2005-10-26 |
2023-08-12 |
human |
| Tatiana Lipina, Viviane Labrie, Ina Weiner, John Rode. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology. vol 179. issue 1. 2005-10-24. PMID:15759151. |
modulators of the glycine site on nmda receptors, d-serine and alx 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. |
2005-10-24 |
2023-08-12 |
mouse |
| Marilyn A Davies, Beth Ann Compton-Toth, Sandra J Hufeisen, Herbert Y Meltzer, Bryan L Rot. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology. vol 178. issue 4. 2005-10-20. PMID:15765260. |
recent studies have suggested that the salutary actions of clozapine in schizophrenia may be due to selective activation of m(1) muscarinic receptors by clozapine and/or its major active metabolite n-desmethylclozapine. |
2005-10-20 |
2023-08-12 |
Not clear |
| Emre Bora, Baybars Veznedaroğlu, Bülent Kayaha. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clinical neuropharmacology. vol 28. issue 3. 2005-10-19. PMID:15965314. |
the effect of galantamine added to clozapine on cognition of five patients with schizophrenia. |
2005-10-19 |
2023-08-12 |
Not clear |
| Emre Bora, Baybars Veznedaroğlu, Bülent Kayaha. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clinical neuropharmacology. vol 28. issue 3. 2005-10-19. PMID:15965314. |
in this case series, the impact of galantamine administration on 5 patients with schizophrenia who had been treated with clozapine are reported. |
2005-10-19 |
2023-08-12 |
Not clear |
| W Danys. CX-516 (Cortex Pharmaceuticals Inc). IDrugs : the investigational drugs journal. vol 2. issue 8. 2005-10-13. PMID:16127658. |
the results of a trial of cx-516 in combination with clozapine in schizophrenia patients were presented at the international society for schizophrenia research in april 1999. |
2005-10-13 |
2023-08-12 |
Not clear |
| Samir Kumar Praharaj, Pankaj Verma, Dipayan Roy, Anuradha Sing. Is clonidine useful for treatment of clozapine-induced sialorrhea? Journal of psychopharmacology (Oxford, England). vol 19. issue 4. 2005-09-08. PMID:15983000. |
oral clonidine (50 to 100 g/day) was tried on 12 stable outpatients of schizophrenia maintained on clozapine. |
2005-09-08 |
2023-08-12 |
Not clear |
| Serdar Murat Dursun, Jaime Eduardo Cecilio Hallak, Peter Haddad, Adrian Leahy, Anne Byrne, Paul Laurence Strickland, Ian Muir Anderson, Antonio Waldo Zuardi, John F William Deaki. Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index? Journal of psychopharmacology (Oxford, England). vol 19. issue 4. 2005-09-08. PMID:15983003. |
clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index? |
2005-09-08 |
2023-08-12 |
Not clear |
| J Steven Lamberti, G Oana Costea, David Olson, John F Crilly, Kumar Maharaj, Xin Tu, Adrienne Groman, Marci B Dietz, Margaret P Bushey, Telva Olivares, Karen Wiene. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. The Journal of clinical psychiatry. vol 66. issue 7. 2005-09-08. PMID:16013906. |
the purpose of this study is to examine the prevalence and clinical-demographic correlates of diabetes among outpatients with dsm-iv-diagnosed schizophrenia or schizoaffective disorder receiving clozapine. |
2005-09-08 |
2023-08-12 |
Not clear |
| Rodrigo A Bressan, Kjell Erlandsson, James M Stone, Rachel S Mulligan, John H Krystal, Peter J Ell, Lyn S Pilowsk. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biological psychiatry. vol 58. issue 1. 2005-09-02. PMID:15992521. |
we used [123i]cns-1261 to determine whether binding to the nmda receptor intrachannel pcp/mk-801 site is affected by schizophrenia or by treatment with typical antipsychotics and clozapine in vivo. |
2005-09-02 |
2023-08-12 |
Not clear |
| Jose de Leon, Francisco J Diaz, Richard C Josiassen, Thomas B Cooper, George M Simpso. Does clozapine decrease smoking? Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 5. 2005-08-26. PMID:15951089. |
smoking and therapeutic response to clozapine in patients with schizophrenia. |
2005-08-26 |
2023-08-12 |
human |
| Chee H Ng, Siow-Ann Chong, Tim Lambert, Agnes Fan, L Peter Hackett, Rathi Mahendran, Mythily Subramaniam, Isaac Schweitze. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. International clinical psychopharmacology. vol 20. issue 3. 2005-08-02. PMID:15812267. |
the present study investigated clozapine dosage, plasma clozapine and metabolite levels, clinical and side-effect profiles in asian versus caucasian patients with chronic schizophrenia who were on stable maintenance treatment. |
2005-08-02 |
2023-08-12 |
Not clear |
| Eila Repo-Tiihonen, Anne Eloranta, Tero Hallikainen, Jari Tiihone. Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients. Neuropsychobiology. vol 51. issue 4. 2005-07-29. PMID:15870506. |
selective serotonin reuptake inhibitor antidepressants have been considered safe in schizophrenia but in combination with clozapine, that is widely used in chronic treatment-resistant schizophrenia, remarkable pharmacokinetic interactions can occur causing an elevation in clozapine plasma levels. |
2005-07-29 |
2023-08-12 |
Not clear |
| Alex Hofer, Martina Hummer, Georg Kemmler, Martin Kurz, Ilsemarie Kurzthaler, W Wolfgang Fleischhacke. The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 3. 2005-07-18. PMID:12974985. |
the safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. |
2005-07-18 |
2023-08-12 |
Not clear |
| Alex Hofer, Martina Hummer, Georg Kemmler, Martin Kurz, Ilsemarie Kurzthaler, W Wolfgang Fleischhacke. The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 3. 2005-07-18. PMID:12974985. |
in addition to its established superiority over other antipsychotics in treatment-resistant patients, clozapine has been consistently shown to improve psychopathology and other psychosocial outcome variables in patients with schizophrenia. |
2005-07-18 |
2023-08-12 |
Not clear |
| Mario Rodrigues Louzã, Debora Pastore Bassit. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years' follow-up. Journal of clinical psychopharmacology. vol 25. issue 2. 2005-07-15. PMID:15738751. |
seven patients meeting diagnostic and statistical manual of mental disorders, revised third edition criteria for chronic exacerbated schizophrenia (mean age 28.5 +/- 10.2 years) and presenting severe td, defined as abnormal involuntary movements scale score above 13, were treated with clozapine and followed up for 5 years. |
2005-07-15 |
2023-08-12 |
Not clear |
| Vicente Molina, Juan D Gispert, Santiago Reig, Javier Sanz, Javier Pascau, Andrés Santos, Manuel Desco, Tomás Palom. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology. vol 178. issue 1. 2005-07-14. PMID:15365682. |
cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. |
2005-07-14 |
2023-08-12 |
Not clear |
| Leslie Citrome, Robert M Bilder, Jan Volavk. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. Journal of psychiatric practice. vol 8. issue 4. 2005-07-13. PMID:15985880. |
clozapine was the first antipsychotic medication to be approved for the indication of treatment-refractory schizophrenia. |
2005-07-13 |
2023-08-12 |
Not clear |